研究单位:[1]Department of Radiotherapy, 307 Hospital of PLA[2]Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150081[3]Hunan Provincial People's Hospital Changsha, Hunan, China, 410005[4]Xiangya Hospital, Central South University Changsha, Hunan, China, 410008[5]Jiangsu Cancer Hospital Nanjing, Jiangsu, China, 210000[6]The fourth hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050010河北医科大学第四医院
The purpose of this study is to compare the short-term and long-term efficacies and the safeties of pirarubicin plus docetaxel(AT group) and pirarubicin plus cyclophosphamide followed by docetaxel(AC-T group) in neoadjuvant chemotherapy of breast cancer.